3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
13
Stomach Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Hepatocellular
3
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Interventions
selpercatinib
2
pembrolizumab
2
130-nm albumin-bound paclitaxel
2
vandetanib
1
trametinib
1
sapanisertib
1
repotrectinib
1
regorafenib
1
pralsetinib
1
methyl N-acetylsibirosaminide
1
lenvatinib
1
fludarabine
1
cemiplimab
1
alectinib
1
aldesleukin
1
Thyrotropin Alfa
1
Presenilin-1
1
Panitumumab
1
Interleukin-15
1
Imatinib Mesylate
1
IT-101
1
IFL protocol
1
Gemcitabine
1
Dacarbazine
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Cetuximab
1
Capecitabine
1
Camptothecin
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Thyroid Neoplasms
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled